Actively Recruiting

Age: 18Years +
All Genders
NCT06854081

EluPro Antibiotic-Eluting BioEnvelope Registry

Led by Elutia Inc. · Updated on 2025-06-17

100

Participants Needed

4

Research Sites

84 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A Multi-Center Registry Study Evaluating Participants Who Receive EluPro Antibiotic-Eluting BioEnvelope During CIED Implantation

CONDITIONS

Official Title

EluPro Antibiotic-Eluting BioEnvelope Registry

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient is undergoing implantation of EluPro with either a de novo CIED implantation or has an existing CIED and is undergoing CIED replacement or upgrade.
  • Patient is willing to comply with scheduled follow-up and study-related visits.
  • Patient is 18 years of age or older at the time of enrollment.
  • Patient agrees to provide written informed consent and use of PHI.
Not Eligible

You will not qualify if you...

  • Patient has a prior history of CIED infection, other prosthetic device infection, or endovascular infection, including endocarditis, in the past 12 months.
  • Patient is exhibiting signs or symptoms consistent with any type of active infection (including but not limited to pneumonia, urinary tract, cellulitis, or bacteremia).
  • Patient has Stage 4 or 5 kidney disease (eGFR <30 ml/min).
  • Patient requires long-term vascular access for any reason.
  • Patient is undergoing implantation of a CIED that does not fit completely into EluPro, preventing closure of the bioenvelope to secure the CIED.
  • Patient is currently on chronic immunosuppressive agents or ≥20mg/day of Prednisone or equivalent.
  • Patient has known allergy to minocycline or rifampin or their derivatives, or any other known contraindications to the implantation of EluPro.
  • Patient is participating in another clinical study that could impact the outcome and documented pre-approval from the study sponsor has not been obtained.
  • Female patient who is pregnant, or of childbearing potential and not on a reliable form of birth control. Women of childbearing potential are required to have a negative pregnancy test within 7 days prior to device procedure.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

UC San Diego Health

La Jolla, California, United States, 92037

Actively Recruiting

2

Tallahassee Research Institute

Tallahassee, Florida, United States, 32308

Actively Recruiting

3

Brigham & Women's Hospital

Boston, Massachusetts, United States, 02115

Actively Recruiting

4

Penn Presbyterian Medical Center

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

Loading map...

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here